Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
| Autor: | Marcela Zenatova, Šárka Pospíšilová, Nikola Tom, Yvona Brychtová, Karla Plevová, Jitka Malčíková, Barbara Dvorackova, Šárka Pavlová, Jakub Hynšt, Jiri Mayer, Michael Doubek, Lenka Radová, Karol Pál, Boris Tichy, Kristyna Zavacka, Anna Panovská, Barbara Kunt Vonkova, Jana Kotašková, Eva Ondroušková |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty endocrine system diseases Chronic lymphocytic leukemia medicine.medical_treatment Immunology Context (language use) Disease Kaplan-Meier Estimate Biochemistry Somatic evolution in cancer Targeted therapy Clonal Evolution stomatognathic system Internal medicine Antineoplastic Combined Chemotherapy Protocols Tumor Cells Cultured Medicine Humans neoplasms Aged Aged 80 and over Lymphoid Neoplasia business.industry Cell Biology Hematology Immunotherapy Middle Aged medicine.disease Genes p53 Leukemia Lymphocytic Chronic B-Cell 3. Good health Cohort Mutation Female Tumor Suppressor Protein p53 IGHV@ business |
| Zdroj: | Blood |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Patients with chronic lymphocytic leukemia (CLL) with TP53 mutations with a >10% variant allele frequency (VAF) are often refractory to chemotherapy and benefit from targeted therapy. Malcikova and colleagues correlated TP53 mutations with Key Points Low-burden TP53 mutations in CLL do not significantly affect the response duration to chemo- and/or immunotherapy, but shorten OS.Clonal expansion of low-burden TP53 mutations in CLL is associated with intense chemoimmunotherapy, but not with targeted therapy. Visual Abstract Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|